Q1 EPS Estimate for Agilent Technologies Lowered by Analyst

Key Points

• Analysts at Leerink Partners have reduced Agilent Technologies' Q1 2026 EPS forecast from $1.42 to $1.34, while the consensus estimate for the full year remains at $5.58 EPS.
• Agilent reported $1.37 EPS for its most recent quarter, matching analysts' expectations, with a 10.1% revenue increase year-over-year to $1.74 billion.
• Six research analysts have rated Agilent stock as a "Buy," while the average target price is set at $139.25, reflecting strong investor interest despite fluctuating price targets among different analysts.

Agilent Technologies, Inc. (NYSE:A - Free Report) - Analysts at Leerink Partnrs lowered their Q1 2026 EPS estimates for shares of Agilent Technologies in a research note issued on Wednesday, August 27th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings per share of $1.34 for the quarter, down from their previous estimate of $1.42. The consensus estimate for Agilent Technologies' current full-year earnings is $5.58 per share.

Several other equities research analysts have also recently commented on A. Wall Street Zen raised Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, June 28th. UBS Group reduced their price objective on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a research report on Thursday, May 29th. Evercore ISI dropped their target price on shares of Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating on the stock in a research report on Thursday. Leerink Partners raised their price target on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a report on Friday, May 30th. Finally, Wells Fargo & Company upped their price target on Agilent Technologies from $135.00 to $140.00 and gave the stock an "overweight" rating in a research note on Thursday. Six research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $139.25.

Agilent Technologies Trading Up 0.5%

Agilent Technologies stock traded up $0.67 during trading hours on Friday, reaching $125.63. 1,781,214 shares of the company's stock were exchanged, compared to its average volume of 1,382,881. The firm's 50 day simple moving average is $118.39 and its 200 day simple moving average is $116.36. Agilent Technologies has a twelve month low of $96.43 and a twelve month high of $153.84. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $35.69 billion, a PE ratio of 29.49, a PEG ratio of 3.91 and a beta of 1.24.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting analysts' consensus estimates of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. During the same period in the prior year, the firm posted $1.32 EPS. The company's quarterly revenue was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the firm's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the transaction, the chief executive officer directly owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Institutional Trading of Agilent Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in Agilent Technologies by 13.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock worth $4,279,000 after acquiring an additional 4,362 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Agilent Technologies by 8.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock valued at $3,606,000 after buying an additional 2,371 shares in the last quarter. Alps Advisors Inc. boosted its holdings in Agilent Technologies by 29.5% in the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock worth $1,563,000 after buying an additional 3,040 shares during the period. D.A. Davidson & CO. raised its holdings in Agilent Technologies by 30.4% during the first quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock valued at $1,108,000 after acquiring an additional 2,207 shares during the period. Finally, LGT Capital Partners LTD. lifted its position in shares of Agilent Technologies by 7.6% in the first quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock valued at $89,870,000 after acquiring an additional 54,302 shares in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.